Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Lingo01:11

Genetic Lingo

Overview
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil-platelet aggregation in β-thalassaemia/haemoglobin E patients.

British journal of haematology·2026
Same author

Beyond iron deficiency: A comprehensive national survey of anaemia etiology in Sri Lankan young adults.

Scientific reports·2026
Same author

Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells.

Molecular medicine (Cambridge, Mass.)·2026
Same author

An In-Depth Analysis of Variable Dynamics Influencing Bone Mineral Density in Transfusion-Dependent Thalassemia Patients.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2025
Same author

Extracellular vesicles modulate endothelial nitric oxide production in patients with β‑thalassaemia/HbE.

Biomedical reports·2025
Same author

Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals.

Scientific reports·2024
Same journal

Corrigendum to: Sortilin as a Culprit in the Atherosclerosis Plaque Progression: Evidence from Clinical and Experimental Studies.

Current molecular medicine·2026
Same journal

Dynamic Expression of Fibroblast Activation Protein (FAP) During Chronic Pancreatitis (CP) Progression in Mice and Evaluation of FAP-targeted Tracers for Early CP Diagnosis.

Current molecular medicine·2026
Same journal

Causal Relationship Between 91 Inflammatory Factors and Gastritis: A Two-Sample Bidirectional Mendelian Randomization Study.

Current molecular medicine·2026
Same journal

Therapeutic Potential of Pistacia Atlantica Gum in Aspirin-Induced Peptic Ulcers: A Dose-Dependent Approach to Mucosal Protection and Hepatorenal Safety.

Current molecular medicine·2026
Same journal

Identification and Characterization of MicroRNAs Associated with Borax-mediated Anti-tumor Activity through High-throughput Technology.

Current molecular medicine·2026
Same journal

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Current molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Genetic modifiers in hemoglobinopathies.

Deborah Rund1, Suthat Fucharoen

  • 1Hematology Department, Hadassah University Hospital, Ein Kerem, Jerusalem Israel IL91120, Israel. rund@cc.huji.ac.il

Current Molecular Medicine
|November 11, 2008
PubMed
Summary
This summary is machine-generated.

Genetic modifiers significantly impact hereditary anemias like thalassemia and sickle cell disease. Understanding these factors is key to improving patient management and treatment strategies.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Hereditary anemias, including thalassemia and sickle cell disease, exhibit significant clinical variability.
  • While primary mutations explain some variation, genetic modifiers play a crucial role in disease presentation and severity.
  • Fetal hemoglobin levels and alpha globin gene copy number are known modifiers influencing phenotype.

Purpose of the Study:

  • To explore the influence of genetic modifiers on the clinical variability of hereditary anemias.
  • To identify genetic factors beyond primary mutations that affect disease phenotype in thalassemia and sickle cell disease.
  • To highlight the role of genetic modifiers in understanding and managing these anemias.

Main Methods:

  • Review of existing literature on genetic variations in hereditary anemias.
  • Analysis of studies investigating the impact of fetal hemoglobin levels and alpha globin gene number.
  • Examination of recent genome-wide studies, including quantitative trait loci (QTLs) analysis.

Main Results:

  • Genetic modifiers, such as alpha globin gene number, can significantly alter the phenotype of thalassemia and sickle cell disease.
  • Elevated fetal hemoglobin levels are a major determinant of phenotype in beta globin genetic diseases.
  • Genome-wide studies are uncovering novel genetic elements that influence HbE/thalassemia and fetal hemoglobin levels.

Conclusions:

  • Genetic modifiers are critical determinants of clinical variability in hereditary anemias.
  • Elucidating the mechanisms of genetic modifiers can lead to more targeted and effective therapeutic strategies.
  • Further research into genetic modifiers promises to enhance the management of thalassemia and sickle cell disease.